6060 results about "Pharmaceutical Substances" patented technology

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

This application provides a method for preparing compound I-b or a pharmaceutically acceptable salt thereof, wherein (S)-N-methylamino-1-(2-thiophene)-1-propanol reacts with 4-fluorobenzo[1,3]dioxolane in a system containing sodium hydride and potassium benzoate to obtain compound I-b. This method has short steps, mild reaction conditions, and is simple to operate, making it suitable for industrial scale-up; moreover, the obtained product has high purity and low isomer content.

The present invention relates to a GLP-1- / GlP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GlP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

The present invention relates to a near-infrared responsive drug delivery system, wherein a near-infrared responsive drug delivery system comprising a near-infrared responsive drug delivery formulation is provided, and the near-infrared responsive drug delivery formulation may include a near-infrared responsive material that generates heat in response to near-infrared rays, and a drug loading formulation that releases a loaded drug as its structure is deformed by the heat generated from the near-infrared responsive material.

1. Name of the product in this design: Medical Compressed Nebulizer (NBC-203). 2. Purpose of this design: To atomize liquid medications for easy oral inhalation. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key features: the front view.

This invention belongs to the field of medical information technology and discloses an intelligent detection system and method for drug compatibility risks. The method includes: establishing and maintaining a multi-dimensional drug compatibility knowledge base based on a graph database; automatically acquiring drug information to be executed and retrieving the target patient's hospital-wide medication history through a standardized medical information interaction interface; calculating the estimated blood drug concentration of each historical drug at the current moment based on a pharmacokinetic compartment model to construct an effective drug list; performing combination analysis on the drugs to be executed and the effective drug list, and executing a multi-level compatibility risk detection algorithm, wherein the detection algorithm includes multi-drug combination cascade reaction risk prediction based on a graph neural network model; and generating and outputting graded early warning information containing risk levels and specific descriptions based on the detection results. This invention achieves dynamic, accurate, and real-time detection of complex multi-drug combination risks, significantly improving medication safety.

[Problem] The purpose of the present invention is to provide a portable anticancer agent container for preventing exposure and infection to the human body caused by chemical solution leakage that arises during a removal operation of a coupling connector at the time of system cleaning using a cleaning solution. [Solution] Provided is a pressurization-type drug injector having a drug exposure preventive function and having a system cleaning function, the pressurization-type drug injector comprising: a reservoir that has a chemical solution filling opening and a chemical solution discharging opening; a pressurization deformation means that undergoes pressurization and deformation by the injection of a chemical solution and that pushes out the chemical solution by a force caused by restoration of the pressurization and deformation; a flow rate control means that adjusts the flow rate of the chemical solution by resistance; a system cleaning port that includes a cleaning solution injection opening, a chemical solution filling opening, and a liquid discharging opening; and a case that contains therein said reservoir, said pressurization deformation means, and said system cleaning port. The case has openings respectively in the vicinity of the chemical solution filling opening, the system cleaning injection opening, and the chemical solution discharging opening. The chemical solution being filled is filled into the pressurization deformation means from the chemical solution filling opening of the reservoir, and moves from the chemical solution discharging opening of the reservoir to the exterior of the container via the flow rate control means. A cleaning solution is injected from the injection opening of the cleaning port arranged downstream from the flow rate control means, and moves to the exterior of the container. The pressurization-type drug injector having a drug exposure preventive function is characterized in that the periphery of the cleaning port is completely covered by a sterile seal, and thus, the cleaning port injection opening is kept clean until use.

A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided, which is useful as a pharmaceutical ingredient having S1P3 receptor antagonistic activity in the prevention and / or treatment an S1P3-mediated disease, wherein all symbols represent the same meaning as the symbols described in the specification. A drug is also provided, which containing, as an active ingredient, a compound having S1P3 receptor antagonistic activity in the prevention and / or treatment an S1P3-mediated disease.

Disclosed in the present invention are a crystalline form of a compound, a preparation method therefor, an active pharmaceutical ingredient or composition comprising same, and a use thereof in the preparation of an extracellular histone inhibitor. The crystalline form of the compound of the present application has high crystallinity, good solid properties and high stability, crystallization conditions are mild, the operation is simple, the process is stable, the cost is low, and the crystalline form of the compound is adapted to be stored as an active pharmaceutical ingredient and produce a formulation product.

The present invention provides a pharmaceutical composition for treating cancer, the pharmaceutical composition comprising a nucleic acid that suppresses the expression of Chromosome 11 Open Reading Frame 97 (C11orf97). With the present invention, it becomes possible to treat cancer.

The application discloses a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative and a synthesis method and application thereof, and relates to a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative which is a compound with the following general formula (I): wherein R1 is selected from,,,,,,,,, and R2 is selected from,,, and. The compound can significantly inhibit the proliferation of leukemia, multiple myeloma, lymphoma, breast cancer, liver cancer and the like at a low dose (nanomole), can effectively degrade IKZF1, IKZF3, BRD4, GSPT1 and CK1 alpha, and has the prospect of being developed into an anti-tumor drug. The application solves the problem that the existing malignant hematological disease treatment drugs have a high safety risk.

The pharmaceutical composition according to the present invention is used at specific therapeutic regimen and dosage, and can be usefully used for the prevention or treatment of fibrosis.

The present application relates to the field of medicinal chemistry and pharmacotherapy, and in particular to a class of bazedoxifene and its preparation method and application. The bazedoxifene derivative is used for gp130 small molecule inhibitor, the compound is a compound shown in formula (I), or a pharmaceutically acceptable salt or ester thereof, and relates to the application of tumor-related activity and the like, in particular the application in preparing drugs for preventing and / or treating diseases related to tumors, especially colorectal cancer.

A drug delivery device may include a housing defining a longitudinal axis and having an opening and a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state. The device may also include plunger moveable toward the distal end of the drug storage container to expel a drug from the drug storage container through the delivery member, the plunger including a body portion having an inner wall defining an axial chamber and an outer wall cooperating with the inner wall to define a body thickness. The device may further include a plunger biasing member disposed at least partially within the axial chamber, the plunger biasing member configured to urge the plunger toward the distal end of the drug storage container.

The present disclosure relates to solid state forms of Compound (1) freebase. The present disclosure also relates to processes for the preparation of the solid state forms, the pharmaceutical compositions comprising the forms, and the use thereof, e.g., in the treatment and prevention of disorders in which NLRP3 activity is implicated.

The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.

This application discloses a linker and its preparation method. The linker includes pharmacophore P, pharmacophore Q, and deoxynucleotides and / or deoxynucleotide derivatives connecting pharmacophore P and pharmacophore Q. Pharmacophore P is obtained by removing the protecting group from group B, and pharmacophore Q is obtained by removing the protecting group from group X. Group B is obtained by chemically modifying the benzylquinolone carboxylic acid pharmacophore, and group X is obtained by chemically modifying the zenomeprazole pharmacophore. The linker is prepared by linking group B and group X with deoxynucleotides and / or deoxynucleotide derivatives to form the linker, including solid-phase synthesis technology. The method of this application can automatically synthesize molecular probes or bivalent drugs containing two pharmacophores, thereby replacing the traditional stepwise linking method, enabling efficient construction of screening libraries, and allowing control of the spatial distance and spatial orientation of the pharmacophores by adjusting the number and base arrangement of deoxynucleotides.

Provided are a pharmaceutical composition and a preparation method therefor. Specifically, provided are an aqueous pharmaceutical composition of a radionuclide-labeled fibroblast activation protein-targeting ligand, and a preparation method therefor. The aqueous pharmaceutical composition has high radiochemical purity.

In one example, a drug delivery system, such as an on-body or off-body delivery system, is configured to deliver a therapeutic drug to a patient. This system comprises a curved track, a plunger, and a driver. The driver translates the plunger along the curved track, causing the plunger's flexible plunger rod to bend along the curved track, driving the plunger seal of the drug container to dispense the liquid drug from the container.

FIELD: neurology; psychiatry.SUBSTANCE: used as a non-pharmacological therapy for autism spectrum disorders in children. The method includes a set of procedures: interval hypoxic-hyperoxic training (HHT), hyperbaric oxygenation and ozone therapy. HHT consists of alternating inhalations of a hypoxic mixture with an oxygen content of 9 to 16 vol.% and a hyperoxic mixture with an oxygen content of 32 to 40 vol.% for a total duration of 45-50 minutes under the control of cardiovascular system parameters. Hyperbaric oxygenation is performed in a pressure chamber under a pressure of 1.3 atmospheres of 100% oxygen mixture, flow of 10 liters per minute, for 45 minutes using a mask. Ozone therapy is performed by rectal insufflation with an ozone-oxygen mixture with an ozone concentration of 85 μg / ml in a volume of 20–30 ml or by intravenous administration of a physiological solution enriched with ozone with an ozone concentration of 85 μg / ml at a rate of 200 ml per 100 ml of physiological solution. The procedures are carried out daily for 12 days.EFFECT: method is effective and has a positive impact on the patient’s condition.1 cl, 1 dwg, 3 ex

This application relates to a pharmaceutical composition of an aquaporin inhibitor and a method for producing the same. The pharmaceutical composition comprises 2-((3,5-bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and meglumine. The pharmaceutical composition of an aquaporin inhibitor and a method for producing the same have the following advantages: the process is simple, easy to operate, conducive to industrial production, good product stability, and a significantly reduced content of degradable impurities, which ensures pharmaceutical efficacy.

The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, a pharmaceutical composition thereof, and a use thereof in the treatment and / or prevention of diseases modulated by wild-type and / or mutant Bcr-Ab11 kinase.

Disclosed are methods and apparatus for delivering an active pharmaceutical ingredient (API) to a substrate, such as an edible. In particular, an API-containing liquid is dosed from a dosing head in small increments. Because the volume of API-containing liquid dosed in each increment is known, and the concentration of API in the API-containing liquid is known, the amount of API incrementally driven out of the dosing head in the API-containing liquid is known. Among the API driven out of the dosing head, a majority can be delivered to the substrate, for instance as individual successive droplets or as a stream. A minority can remain adhered to the dosing head as a residual API. A wash fluid can be applied to the dosing head to remove the residual API and deliver the residual API to the substrate.